New Insights Into Hepatic Impairment (HI) Trials

Area of Science:

• Pharmacology
• Clinical Drug Development
• Hepatology

Background:

• Hepatic impairment (HI) necessitates dose adaptation in drug development due to altered drug metabolism.
• Traditional HI trials assess dose needs in patients with liver disease.
• This review synthesizes data from HI studies to refine trial designs.

Purpose of the Study:

• To analyze existing hepatic impairment (HI) study data.
• To categorize HI effects on drug pharmacokinetics (PK).
• To identify patterns for optimizing HI trial designs and drug dosing.

Main Methods:

• Reviewed 436 HI studies, extracting PK data for 273 compounds.
• Categorized compounds as 'positive' or 'negative' based on AUC/Cmax ratios (≥2 or ≤0.5) between HI patients and controls.
• Analyzed PK properties of compounds with steep increases in AUC ratios across HI severity.

Main Results:

• 199 compounds were negative, 69 positive (ups), and 5 positive (downs).
• 14 of 69 positive compounds showed a steep increase in AUC ratios from mild to severe HI.
• Steep increase compounds often had high protein binding, high Vd, low bioavailability, minor renal elimination, and were CYP3A4/2D6 substrates, frequently OATP1B1 substrates.

Conclusions:

• Drug PK patterns in HI can inform dose adaptation strategies.
• Compounds with steep PK changes across HI severity may require full trials but allow dose estimation.
• Compounds with minimal PK changes may allow for reduced HI trials, potentially focusing on moderate HI.